Lv1
20 积分 2022-12-27 加入
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
8天前
已完结
The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition
11天前
已完结
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
23天前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
1个月前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
1个月前
已完结
Decrease in serum asprosin levels following six weeks of spinning and stationary cycling training in overweight women
1个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
3个月前
已完结
BPROAD — End of the Road for Debate on Systolic Blood-Pressure Goals in Type 2 Diabetes?
3个月前
已完结
Insulin plus metformin for T2DM—are there benefits?
3个月前
已完结
Body Fat Distribution, Diabetes Mellitus, and Cardiovascular Disease: an Update
3个月前
已完结
皖公网安备34019202002308
